Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 901–943 of 943
NMDA Receptor Mediated Mechanisms in the Post-Stroke Brain: From Physiology to Pathology
Gong, H., Wang, X.-Z., Liu, D., Liu, W.-J., Xiaoxia, D., & Rao, J. (2026) · Biomolecules · doi:10.3390/biom16060770 · Cited by 1
“In contrast, low-affinity NMDAR antagonists with rapid dissociation kinetics, such as amantadine and memantine, have demonstrated clinical benefits in other neurological conditions, including Parkinson’s disease-related motor and cognitive impairments [125,126].”
Zhang, J., Shahatiaili, A., Hou, Y., Zhou, N., Huang, K., Wang, X., Wang, D. L., Yu, Z., Feng, X., & Gao, Y. (2026) · Biomedicines · doi:10.3390/biomedicines14061196
“It preferentially blocks pathologically over‑activated chan‑ nels while sparing physiological neurotransmission, thus offering an excellent safety pro‑ file [40,41].”
NMDA receptor–dependent structural plasticity links early life stress to persistent aggression
Jacobs, J. T., & Nordman, J. C. (2026) · Neurobiology of Stress · doi:10.1016/j.ynstr.2026.100831
“Although ketamine and memantine both block NMDARs, they differ in pharmacological properties that may contribute to divergent behavioral effects following stress exposure (Lipton, 2006; Paoletti et al., 2013; Zanos and Gould, 2018).”
Ni, X., Zhou, S., He, X., Wu, K., Liang, G., Wang, A., & Xu, X. (2026) · Toxicology in Vitro · doi:10.1016/j.tiv.2026.106274
Unveiling the Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Karati, D., Meur, S., Sen, P., Mukherjee, S., & Ghosh, P. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010004
Cholesterol at the Center of Alzheimer’s Disease: A Unifying Hypothesis on the Pathogenic Mechanism
Zhu, B. T. (2026) · Molecules · doi:10.3390/molecules31142418
Dicationic open-channel blockers of glutamate receptors: clinical prospects (a review)
Гмиро, В. Е. (2026) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf697076
Mirzazadeh, H., Sadeghi, E., Mostafavi, S., Namazee, M., Ashourzade, A. H., Moshfeghinia, R., & Rahimi, S. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08398-y
“Memantine acts as an uncompetitive, low-affinity NMDA receptor antagonist, preferentially inhibiting excessive receptor activation while largely sparing physiological neurotransmission, with effects that depend on prior receptor activation [42].”
Modulating glutamate neurotransmission in in vivo models of Multiple Sclerosis: a narrative review
Stamoula, E., Vavilis, T., Boskou, I., Vampertzi, O., Floropoulou, N., Demopoulos, A., Grigoriou, R., & Melnikov, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1811323
“It has been argued by Lipton et al. that early high-af fi nity NMDA antagonists failed clinically primarily because their tolerated doses failed to reach neuroprotective thresholds without producing unacceptable neuropsychiatric side effects (109).”
Khola, N. U. H., Hayat, M., Muzaffar, I., & Ahmed, T. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05296-y
Salunkhe, J., & Ugale, V. G. (2026) · Drug Development Research · doi:10.1002/ddr.70367
Mechanism of activity inversion for GluN2B-selective negative allosteric modulators
Kell, S. A., Myers, S. J., Tahirovic, Y. A., Mosley, C. A., Santangelo, R., Liotta, D. C., & Traynelis, S. F. (2026) · Molecular Pharmacology · doi:10.1016/j.molpha.2026.100154
Zhigulin, A. S., Nikolaev, M. V., Dron, M. Y., Vasilenko, D. A., Barygin, O. I., & Tikhonov, D. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177723
“For example, the kinetics and mechanism of action determine the effectiveness and tolerability of the NMDAR antagonist memantine [31] and the AMPAR antagonist perampanel [5,32,33].”
Angel, I., Caraco, Y., Sternberg, C., Wanounou, M., Blotnick, S., Mujahed, W., & Aminov, E. (2026) · doi:10.22541/authorea.15008177/v1
Mechanisms of NMDA receptor inhibition by fluoroethylnormemantine – comparison with memantine
Furman, V. V., Zhigulin, A. S., & Barygin, O. I. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179334
Reboxetine blocks NMDA receptors in a voltage-, use-, and activity-dependent manner
Föhr, K. J., Jungwirth, B., Schrezenmeier, H., & Messerer, D. A. C. (2026) · Scientific Reports · doi:10.1038/s41598-026-72181-y
“Here, drugs such as MK-801 with a slow off-rate, resulting in a high affinity, have been found to be of limited therapeutic utility 11 .”
Papadopoulou, K., Tsokkou, S., Pavlidis, P., Karachrysafi, S., Tseriotis, V., Kavvadas, D., Kavvada, A., Sardeli, C., Kouvelas, D., Meditskou, S., et al. (2026) · Neurology International · doi:10.3390/neurolint18100180
“NMDA-receptor antagonism, using an already licensed and generally well-tolerated agent such as memantine [17,18], is one such strategy worth pursuing in future preclinical and clinical work.”
InfluentialIntharuksa, A., Prasansuklab, A., Techarang, T., Chaikhong, K., Arunotayanun, W., & Jenraumjit, R. (2026) · Nutrients · doi:10.3390/nu18193126
“Pharmacological modulation of NMDA receptors using non-competitive antagonists such as memantine provides partial neuroprotection by reducing pathological receptor activation while preserving physiological signaling [35].”
InfluentialSeweje, O. D. (2026) · Lu Zone Ul (Laurentian University)
Thabet, Y., Neville, S. E., Shafau, A. O., Graham, D. L., & Stanwood, G. D. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00338-6
“Although it produces an acute condition rather than a chronic and progressive one, NMDA receptor antagonists reproduce positive, negative, and cognitive endophenotypes in rodents [28, 29].”
InfluentialStrength of weakness in molecular interactions: toward transient medicines in drug discovery
Ohlson, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104816
Angel, I., Caraco, Y., Sternberg, C., Wanounou, M., Blotnick, S., Mujahed, W., & Aminov, E. (2026) · doi:10.22541/authorea.15009655/v1
Dhurandhar, Y., Tomar, S., Bisen, V., & Namdeo, K. P. (2026) · Medical Hypotheses · doi:10.1016/j.mehy.2026.112208
Lu, H., Zheng, J., Luo, N., Zhang, C., Liu, X., Wang, X., Liu, Y., Ling, Y., & Su, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1974944
BindingDB Entry 50031861: Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues.
BindingDB (2010) · UC San Diego · doi:10.7270/q2k937qf
BindingDB (2020) · UC San Diego · doi:10.7270/q218393w
BindingDB (2013) · UC San Diego · doi:10.7270/q2c82bd2
BindingDB (2020) · UC San Diego · doi:10.7270/q23b62rz
Brittain, M. K. (2012) · IUScholarWorks (Indiana University) · doi:10.7912/c2/299
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.